circulating concentrations. Although it is sometimes possible to identify individual patients with very poor compliance, for instance by a marked improvement in disease control with supervised administration of oral drugs as an inpatient,5 it is much more difficult to measure compliance in groups of patients such as those participating in clinical trials. The methods traditionally used for measuring compliance in this situation are far from adequate and all of those methods overestimate compliance. Table 1 summarises the available methods of measuring compliance.
Studies of compliance with antirheumatic drugs
A number of compliance studies with antirheumatic drugs have been carried out using most of the currently available methods of assessing compliance. Deyo et al, using 'medication refills' to measure compliance, found that more than 50% of patients taking prednisone and over 80% of patients taking aspirin obtained 80% or less of the necessary number of refills to ensure continuous treatment over six months.25 These authors also looked at compliance with penicillamine and a number of nonsteroidal anti-inflammatory drugs (NSAIDs) and attempted to relate compliance to diagnosis. These data, however, are very difficult to interpret as they describe the mean compliance for each drug. A mean compliance with penicillamine of 84-4% could imply that at the extremes 15% of patients took no treatment and the rest had 100% compliance or that all patients took 84-4% of their tablets, two patterns of compliance which could have totally different 872 Pullar, Kumar, Feely effects on the outcome of treatment. An interview based comparison of compliance with diclofenac 25 mg four times a day and diclofenac 100 mg sustained release once daily found that almost twice the total quantity of drug was missed on the first regimen compared with the once daily preparation. 26 One study of 123 patients attending a rheumatology clinic attempted to classify compliance with drug treatment into 'full' and 'partial! poor' using the impression of the physician, who also had access to blood salicylate measurements. These authors classified 78 (63%) as having full compliance. 12 A recent community based study using interview found that 63-5% of 178 patients with rheumatoid arthritis claimed that they did not alter their dose of drugs from that instructed. 27 Recently we examined compliance, using a pharmacological marker (low dose phenobarbitone), in 26 rheumatoid patients who had shown a poor response to high doses of D-penicillamine and found incomplete compliance in 11 (42%), only one of whom could be identified by interview, six by return tablet count, and six by clinician's impression. 6 The definition of inadequate compliance in this study was determined to give patients the 'benefit of the doubt' and probably, ip fact, many more of these patients had incomplete compliance.
Patterns of compliance and their possible impact on clinical trials
The various methods used to measure compliance may result in different estimates of compliance. This is best illustrated by the results of two studies of compliance by children given phenoxymethylpenicillin for streptococcal sore throat, one of which found that 83% of children had stopped treatment by day 9,28 whereas the other found that 89% of children were still taking the drug on day 9 or 10.29
The studies described in the previous section span three continents make the following recommendations: (a) the limitations of any method used should be appreciated and discussed; (b) compliance should be described by placing patients into broad 'bands' of compliance with information being given on the number of patients in each band; (c) inadequate compliance should be defined in a way which is appropriate to the pharmacology of the drug under scrutiny and the method used to measure compliance. It should relate to a level of compliance in an individual at which the desired pharmacodynamic effects of the drug might be attenuated; (d) it should be stated in the protocol how data from patients who fulfil the criteria of inadequate compliance as designated in (c) will be handled in the analysis of results.
To use the analogy with statistics we do not expect that these proposals will lead us from the unsupported p values of 20 years ago to today's confidence intervals, power calculations, and odds ratios overnight, but hopefully they may stimulate a more rational approach to compliance in clinical trials.
